Prosecution Insights
Last updated: April 19, 2026

Chong Kun Dang Pharmaceutical Corp.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
2
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18010399 INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE VARADARAJ, ARCHANA 1658 Non-Final OA Dec 14, 2022
17995947 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME REILLY, SOPHIA JANE 1627 Non-Final OA Oct 11, 2022
17801057 PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE HAVING EXCELLENT RELEASE PROPERTIES WESTERBERG, NISSA M 1618 Final Rejection Aug 19, 2022
17614967 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same LEE, CHIHYI NMN 1628 Final Rejection Nov 29, 2021

Managing Chong Kun Dang Pharmaceutical Corp.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month